State University of New York Upstate Medical Center, Syracuse, NY.
University of Texas Southwestern Medical Center, Dallas, TX.
Urol Oncol. 2024 Jan;42(1):20.e17-20.e23. doi: 10.1016/j.urolonc.2023.07.004. Epub 2023 Jul 28.
UGN-101 has been approved for the chemoablation of low-grade upper tract urothelial cancer (UTUC) involving the renal pelvis and calyces. Herein is the first reported cohort of patients with ureteral tumors treated with UGN-101.
We performed a retrospective review of patients treated with UGN-101 for UTUC at 15 high-volume academic and community centers focusing on outcomes of patients treated for ureteral disease. Patients received UGN-101 with either adjuvant or chemo-ablative intent. Response rates are reported for patients receiving chemo-ablative intent. Adverse outcomes were characterized with a focus on the rate of ureteral stenosis.
In a cohort of 132 patients and 136 renal units, 47 cases had tumor involvement of the ureter, with 12 cases of ureteral tumor only (8.8%) and 35 cases of ureteral plus renal pelvic tumors (25.7%). Of the 23 patients with ureteral involvement who received UGN-101 induction with chemo-ablative intent, the complete response was 47.8%, which did not differ significantly from outcomes in patients without ureteral involvement. Fourteen patients (37.8%) with ureteral tumors had significant ureteral stenosis at first post-treatment evaluation, however, when excluding those with pre-existing hydronephrosis or ureteral stenosis, only 5.4% of patients developed new clinically significant stenosis.
UGN-101 appears to be safe and may have similar efficacy in treating low-grade urothelial carcinoma of the ureter as compared to renal pelvic tumors.
UGN-101 已获准用于肾盂和肾盏低级别上尿路尿路上皮癌（UTUC）的化学消融。本文报告了首例采用 UGN-101 治疗输尿管肿瘤的患者队列。
我们对 15 个高容量学术和社区中心的 132 例患者和 136 个肾脏单位进行了 UGN-101 治疗 UTUC 的回顾性研究，重点关注治疗输尿管疾病的患者的结局。患者接受 UGN-101 辅助或化学消融治疗。报告了接受化学消融治疗的患者的反应率。对不良结局进行了特征描述，重点关注输尿管狭窄的发生率。
在 132 例患者和 136 个肾脏单位中，47 例患者输尿管受累，其中 12 例仅输尿管肿瘤（8.8%），35 例输尿管加肾盂肿瘤（25.7%）。23 例接受 UGN-101 诱导性化学消融治疗的输尿管受累患者中，完全缓解率为 47.8%，与无输尿管受累患者的结局无显著差异。14 例（37.8%）有输尿管肿瘤的患者在首次治疗后评估时出现明显的输尿管狭窄，但在排除存在肾盂积水或输尿管狭窄的患者后，仅有 5.4%的患者出现新的有临床意义的狭窄。
与肾盂肿瘤相比，UGN-101 似乎安全，且在治疗低级别输尿管尿路上皮癌方面可能具有相似的疗效。
